API
REGN icon

Advisor Partners II’s Regeneron Pharmaceuticals REGN Stock Holding History

Advisor Partners II’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		$2.63M Buy
3,190
+317
+11% +$249K 0.11% 204
2023
Q2 		$2.06M Buy
2,873
+179
+7% +$138K 0.1% 207
2023
Q1 		$2.21M Buy
2,694
+417
+18% +$315K 0.12% 167
2022
Q4 		$1.64M Buy
2,277
+416
+22% +$307K 0.1% 223
2022
Q3 		$1.28M Buy
+1,861
New +$1.17M 0.1% 224

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Advisor Partners II's REGN Position: Q3 2023 in Review

Advisor Partners II increased its Regeneron Pharmaceuticals (REGN) stake by 11% in Q3 2023, buying an estimated $249K and bringing the position to 3,190 shares worth $2.63M. The position accounts for 0.11% of the portfolio, ranked #204.

Advisor Partners II first reported a position in REGN in Q3 2022 and has held it in 5 quarters since. 1,177 funds tracked by Wall St. Rank hold REGN as of Q3 2023.

  • Advisor Partners II held 3,190 shares of Regeneron Pharmaceuticals worth $2.63M as of Q3 2023.
  • Advisor Partners II bought 317 Regeneron Pharmaceuticals shares in Q3 2023, an estimated $249K.
  • Regeneron Pharmaceuticals made up 0.11% of Advisor Partners II's portfolio in Q3 2023, its #204 holding.
  • Advisor Partners II first reported a position in Regeneron Pharmaceuticals in Q3 2022 and has held it in 5 quarters since.
  • 1,177 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2023.

Based on Advisor Partners II's 13F filing for Q3 2023, filed 26 Oct 2023.